ACR Updates: COVID-19

 

An Important Message from the ACR

The ACR wishes to express strong support for Dr. Anthony Fauci and his continued and close involvement in the work to address the nation’s response to the COVID-19 pandemic.
Read More

 

Breaking News

ACR COVID-19 Clinical Guidance for Pediatric Patients Town Hall Meeting: August 11

The ACR has developed clinical guidance for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C) and hyperinflammation. During this special town hall event on August 11, 7:30 – 9:00 PM ET, members of the task forces who developed the guidance will review the recommendations. Pre-registration is required.
Register for Town Hall

 

Senate Majority Releases Proposed Draft of Next COVID-19 Package

On July 27, the Senate majority released a draft of what they would like to see in the next COVID-19 package of legislation. This draft is just a starting point but includes many notable provisions. Provided is an overview of the process, timeline, and policies included.
View Proposed Draft
  - New

 

Updated Guidance from the American College of Rheumatology: Reopening Strategies During the COVID-19 Pandemic

This updated guidance from the ACR is intended for rheumatologists and rheumatology health professionals to consider as they evaluate local conditions, design reopening procedures, monitor progress, and advise staff and patients during the COVID-19 pandemic. The updated guidance includes strategies for safe return of staff and patients to the clinic for a visit or to work following suspected or confirmed infection with SARS-CoV-2. A test-based strategy is no longer recommended, except in certain cases. A symptom-based strategy is recommended, with a longer period recommended for those who had severe or critical COVID-19 or who are severely immune compromised.
View Guidance
  - Updated July 26, 2020

 

See All Breaking News

 

Practice and Advocacy Resources

ACR COVID-19 practice and advocacy resourcesThe ACR’s COVID-19 Practice and Advocacy Task Force continues to work rapidly to provide support to you during this unprecedented time. You’ll find guidance documents that include approaches to drug shortages, support for telehealth, information about federal stimulus relief aid, and guidance for infusions. Working with experts in COVID-related topics, we are focused on developing meaningful information and resources to help guide you.

Practice and Advocacy Resources

COVID-19 Manufacturer Resources and Patient Assistance Programs  - New

 

Clinical Guidance for Pediatric Patients

ACR COVID-19 clinical guidance for pediatric patients with rheumatic diseasesThe ACR has developed two new clinical guidance documents for pediatric patients in the context of the COVID-19 pandemic, including for the care of children with pediatric rheumatic disease, and for the management of inflammatory syndromes in children with recent or concurrent infections with SARS-CoV-2, specifically Multisystem Inflammatory Syndrome in Children (MIS-C). All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

 



COVID-19 Clinical Guidance Summary for Pediatric Patients with Rheumatic Disease   - June 18, 2020

ACR Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1   Published - July 23, 2020

How to cite this article: Wahezi DW, Lo MS, Rubinstein TB, Ringold S, Ardoin SP, Downes KJ, et al. American College of Rheumatology Guidance for the Management of Children with Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41455. E-pub ahead of print.

The recommendations for pediatric rheumatology patients address various treatment options and provide general guidance, as well as direction for when to start, stop or reduce medications.


Clinical Guidance Summary for Pediatric Patients with MIS-C Associated with SARS-CoV-2 and Hyperinflammation in COVID-19   Updated - July 22, 2020

ACR Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 1   Published - July 23, 2020

How to cite this article: Henderson LA, Canna SW, Friedman KG, Gorelik M, Lapidus SK, Bassiri H, et al. American College of Rheumatology Clinical Guidance for Pediatric Patients with Multisystem Inflammatory Syndrome in Children (MIS‐C) Associated with SARS‐CoV‐2 and Hyperinflammation in COVID‐19. Version 1. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41454. E-pub ahead of print.

The recommendations for MIS-C focus on general guidance, diagnostic evaluation, and therapy options, as well as comparing and contrasting the features of MIS-C and Kawasaki Disease. For hyperinflammation in COVID-19, the recommendations also focus on general guidance, as well as immunomodulatory treatment. 

You can also access the clinical guidance information on your iOS or Android mobile device. Download the free ACR Guideline and Criteria App on the App Store or Google Play.

 

Clinical Guidance for Adult Patients with Rheumatic Diseases

ACR COVID-19 clinical guidance for patients with rheumatic diseasesThe ACR has developed clinical guidance for the care of adult patients with rheumatic diseases during the COVID-19 pandemic. Populations considered include patients with a documented COVID-19 infection, those who are stable following exposure to SARS-CoV-2 (but without known infection), and patients who are stable with no infection or exposure. The recommendations address various treatment options and provide general guidance, as well as direction for when to start, stop, or reduce medications. All recommendations are based on current knowledge and will be revised as circumstances and evidence evolve.

 

 

COVID-19 Clinical Guidance Summary for Adult Patients with Rheumatic Diseases   Updated - July 13, 2020

American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2   Published  - July 30, 2020

How to cite this article: Mikuls TR, Johnson SR, Fraenkel L, Arasaratnam RJ, Baden LR, Bermas BL, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID‐19 Pandemic: Version 2. Arthritis Rheumatol doi: https://onlinelibrary.wiley.com/doi/10.1002/art.41437. E-pub ahead of print.

You can also access the clinical guidance information on your iOS or Android mobile device. Download the free ACR Guideline and Criteria App on the App Store or Google Play.

 

COVID-19 State-of-the-Art Clinical Symposium Recordings

COVID-19 State-of-the-Art Clinical Symposium RecordingsWatch three of our featured COVID-19 sessions recorded during the virtual 2020 State-of-the-Art Clinical Symposium, presented by rheumatology thought leaders Jinoos Yazdany, MD, MPH, and Mehrdad Matlloubian, MD, PhD.

 

COVID-19 Epidemiology, Transmission and Insights from Global Registry Data  

Immunology of COVID-19 and Potential Treatments  

2020 SOTA COVID-19 Panel Q&A with Jinoos Yazdany, MD, MPH, and Mehrdad Matloubian, MD, PhD  

 

Global Rheumatology Alliance

COVID-19 Global Rheumatology AllianceThe COVID-19 Global Rheumatology Alliance, a section of the American College of Rheumatology, is a provider-entered registry aiming to collect data on rheumatology patients with COVID-19 and hopes the information will provide guidance for rheumatology professionals when assessing and treating the infection in patients with rheumatic disease.

The Global Rheumatology Community’s Response to the Worldwide COVID-19 Pandemic  

Help Us Help Patients: Report a COVID-19 Case  

 

COVID-19: The Rheumatologist

COVID-19: Wiley Journal Articles

Mental Health & Well-being Resources

ACR Meetings and Program Updates

 

 

Experiencing COVID-19 related drug shortages, practice issues, or any other problems?
Share your comments and questions with us at COVID@rheumatology.org

Updated August 5, 2020 at 1:00 PM ET

© 2020 American College of Rheumatology.  All rights reserved.  Website & Privacy Policies | Sitemap | Help | Contact Us